InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Partners with CRO to Advance NV-387 Antiviral Drug to Phase II Trials
NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization ("CRO") to conduct a Phase II clinical trial for its broad-spectrum antiviral drug, NV-387. The host-mimetic drug, which mimics cellular attachment receptors to block viral infections, has demonstrated strong antiviral activity in preclinical models against orthopoxviruses, including MPox and Smallpox, and outperformed existing antiviral treatments in other infection models. The trial will…